Skip to main content
VKTX
NASDAQ Life Sciences

Viking Closes $548M Concurrent Offering After Full Over-Allotment Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$33.28
Mkt Cap
$3.853B
52W Low
$24.88
52W High
$43.15
52W Position info
34% above low
Off High info
23% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

VKTX sits 34% above its 52-week low of $24.88 on elevated volume (2.4× avg).

Summary

Viking Therapeutics closed its $548 million concurrent equity and convertible notes offering after underwriters fully exercised both over-allotment options, adding approximately $547.8 million in net proceeds for its obesity and metabolic pipeline.


Key Events · Financing and Capital Events · VKTX

  • Concurrent Offering Closed

    Viking closed its upsized concurrent offering on September 25, 2026, with underwriters fully exercising both over-allotment options.

  • Equity Tranche Expanded

    The common stock offering grew to 9,035,714 shares at $35.00 per share, generating approximately $297.0 million in net proceeds after discounts and expenses.

  • Convertible Notes Tranche Expanded

    The 2.00% convertible senior notes due 2032 tranche increased to $258.75 million principal amount, adding approximately $250.8 million in net proceeds at a $50.75 conversion price.

  • Use of Proceeds

    Combined net proceeds of approximately $547.8 million fund continued clinical development of VK2735 and VK3019, plus general R&D and working capital.


Analysis · VKTX · Life Sciences

Viking Therapeutics closed its upsized concurrent offering on September 25, 2026, with underwriters exercising in full their over-allotment options for both tranches. The equity offering grew to 9,035,714 shares at $35.00, generating approximately $297.0 million in net proceeds, while the convertible notes tranche expanded to $258.75 million principal amount, adding approximately $250.8 million in net proceeds. Combined net proceeds of roughly $547.8 million fund the VK2735 and VK3019 clinical programs. The full exercise of both options signals strong institutional demand, though the equity tranche priced at a discount to the $41.65 last reported sale price on September 23, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VKTX was trading at $33.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $24.88 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VKTX - Latest Insights

VKTX
Oct 29, 2026, 10:43 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $27.18
Real-time Price: $26.15 info
Change: -$1.03 (-4%) info
Market Cap: $3.337B info
VKTX
Oct 28, 2026, 5:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $24.70
Real-time Price: $26.15 info
Change: +$1.45 (+6%) info
Market Cap: $3.337B info
VKTX
Oct 28, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.38
Real-time Price: $26.15 info
Change: +$1.77 (+7%) info
Market Cap: $3.337B info
VKTX
Oct 28, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.41
Real-time Price: $26.15 info
Change: +$0.740 (+3%) info
Market Cap: $3.337B info
VKTX
Sep 28, 2026, 4:30 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $33.16
Real-time Price: $26.15 info
Change: -$7.01 (-21%) info
Market Cap: $3.337B info